SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study) - Bruminhent, Jackrapong; Sethaudom, Chavachol; Chaumdee, Pongsathon; Boongird, Sarinya; Kiertiburanakul, Sasisopin; Malathum, Kumthorn; Nongnuch, Arkom; Phuphuakrat, Angsana; Jirasiritham, Sopon; Janphram, Chitimaporn; Thotsiri, Sansanee; Upama, Supparat; et al. (medRxiv, 2021)
Immunogenicity following inactivated SARS-CoV-2 vaccination among solid organ transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 non-transplant controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median age of KT recipients was 50 years (IQR, 42–54) and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median time since transplant was 4.5 years (IQR, 2–9.5). Among 35 KT patients, anti-RBD IgG titer after vaccination was not significantly different to baseline, but was significantly lower than in controls (7.8 [95%CI 0.2–15.5] vs 2,691 [95%CI 1,581–3,802], p<0.001) as well as the percentage of surrogate virus neutralizing antibody inhibition (2 [95% CI −1-6] vs 71 [95%CI 61–81], p<0.001). However, the mean of SARS-CoV-2 mixed peptides-specific T-cell responses measured by enzyme-linked immunospot assays was significantly increased compared with baseline (66 [95%CI 36–99] vs. 34 [95%CI 19–50] T-cells/106 PBMCs, p=0.02) and comparable to that in controls. Our findings revealed weak HMI and marginal CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccine. (Thai Clinical Trials Registry, TCTR20210226002).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThai Clinical Trials Registry, TCTR20210226002.Funding StatementThis study received a grant from the National Research Council of Thailand (NRCT), Ministry of Higher Education, Science, Research, and Innovation of Thailand in collaboration with the Department of Medical Services, Ministry of Public Health of Thailand (102912).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients provided written consent. The Institutional Review Board of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, reviewed and approved the study protocol (approval number: MURA2021/242).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon appropriate request.ACE2angiotensin-converting enzyme 2AEadverse eventsCIconfidence intervalCMISARS-CoV-2-specific cell-mediated immunityCOVID-19coronavirus disease 2019ELISpotenzyme-linked immunospot assayHMISARS-CoV-2-specific humoral immunityIFN-γinterferon-γIgGimmunoglobulin GIQRinterquartile rangeKTkidney transplantMSARS-CoV-2 membrane proteinmRNAmessenger ribonucleic acidNSARS-CoV-2 nucleoproteinORFopen reading framePBMCperipheral blood mononuclear cellRBDreceptor binding domainRT-PCRreverse-transcription polymerase chain reactionSSARS-CoV-2 spike glycoproteinSARS-CoV-2severe acute respiratory syndrome coronavirus 2 SFU spot forming unitsSMNOSARS-CoV-2 spike protein, nucleoprotein, membrane protein and ORF-3a, and ORF-7a proteinsSOTsolid organ transplantationsVNTSARS-CoV-2 surrogate virus neutralization test